CORRESP Filing
ADIAL PHARMACEUTICALS, INC.
Date: Dec. 15, 2025 · CIK: 0001513525 · Accession: 0001213900-25-121686
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292110
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason Drury Adial Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed on December 12, 2025 File No: 333-292110 Request For Acceleration
Re:
Dear Mr. Drury:
Adial Pharmaceuticals, Inc . (the " Registrant ") hereby requests that the United States Securities and Exchange Commission (the " Commission ") take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-292110) (the " Registration Statement "), to become effective on Wednesday, December 17, 2025, at 4:00 p.m ., Eastern Time, or as soon thereafter as is practicable.
The Registrant understands that the Staff of the Commission will consider this request for acceleration of the effective date of the Registration Statement as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws, including the Securities Act of 1933, as amended, as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes its counsel, Leslie Marlow, Esq. or Patrick Egan, Esq. of Blank Rome LLP, to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (212) 885-5358 or Mr. Egan at (212) 885-5346 with any questions you may have concerning this request, and please notify either Ms. Marlow or Mr. Egan when this request for acceleration has been granted.
Very truly yours,
ADIAL PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm Adial Pharmaceuticals, Inc. 4870 Sadler Road, Suite 300 Glen Allen, Virginia 23060 (310) 988-0643 December 15, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason Drury Re: Adial Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed on December 12, 2025 File No: 333-292110 Request For Acceleration Dear Mr. Drury: Adial Pharmaceuticals, Inc . (the " Registrant ") hereby requests that the United States Securities and Exchange Commission (the " Commission ") take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-292110) (the " Registration Statement "), to become effective on Wednesday, December 17, 2025, at 4:00 p.m ., Eastern Time, or as soon thereafter as is practicable. The Registrant understands that the Staff of the Commission will consider this request for acceleration of the effective date of the Registration Statement as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws, including the Securities Act of 1933, as amended, as they relate to the issuance of the securities covered by the Registration Statement. The Registrant hereby authorizes its counsel, Leslie Marlow, Esq. or Patrick Egan, Esq. of Blank Rome LLP, to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (212) 885-5358 or Mr. Egan at (212) 885-5346 with any questions you may have concerning this request, and please notify either Ms. Marlow or Mr. Egan when this request for acceleration has been granted. Very truly yours, ADIAL PHARMACEUTICALS, INC. By: /s/ Cary J. Claiborne Name: Cary J. Claiborne Title: President and Chief Executive Officer cc: Vinay Shah, Chief Financial Officer, Adial Pharmaceuticals, Inc. Leslie Marlow, Esq. and Patrick J. Egan, Esq., Blank Rome LLP